Crizotinib remains the standard treatment for previously untreated patients with ALK + NSCLC (Riely et al., 2024; China clinical practice guideline for stage IV primary lung cancerChinese Association for Clinical Oncologists, 2024). The gene discussed is ALK; the disease is non-small cell lung carcinoma.